<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167374</url>
  </required_header>
  <id_info>
    <org_study_id>PROMETHEUS-01</org_study_id>
    <nct_id>NCT01167374</nct_id>
  </id_info>
  <brief_title>Carbon Ion Radiotherapy for Hepatocellular Carcinoma</brief_title>
  <acronym>PROMETHEUS-01</acronym>
  <official_title>Phase I Study Evaluating the Treatment of Patients With Hepatocellular Carcinoma (HCC) With Carbon Ion Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment options for patients with advanced hepatocellular carcinoma (HCC) are often&#xD;
      limited. In most cases, they are not amenable to local therapies including surgery or&#xD;
      radiofrequency ablation. The multi-kinase inhibitor sorafenib has shown to increase overall&#xD;
      survival in this patient group for about 3 months.&#xD;
&#xD;
      Radiation therapy is a treatment alternative, however, high local doses are required for&#xD;
      long-term local control. However, due to the relatively low radiation tolerance of liver&#xD;
      normal tissue, even using stereotactic techniques, delivery of sufficient doses for&#xD;
      successful local tumor control has not be achieved to date.&#xD;
&#xD;
      Carbon ions offer physical and biological characteristics. Due to their inverted dose profile&#xD;
      and the high local dose deposition within the Bragg peak precise dose application and sparing&#xD;
      of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an&#xD;
      increased relative biological effectiveness (RBE), which can be calculated between 2 and 3&#xD;
      depending on the HCC cell line as well as the endpoint analyzed.&#xD;
&#xD;
      Japanese Data on the evaluation of carbon ion radiation therapy showed promising results for&#xD;
      patients with HCC.&#xD;
&#xD;
      In the current Phase I-PROMETHEUS-01-Study, carbon ion radiotherapy will be evaluated for&#xD;
      patients with advanced HCC. The study will be performed as a dose-escalation study evaluating&#xD;
      the optimal carbon ion dose with respect to toxicity and tumor control.&#xD;
&#xD;
      Primary endpoint is toxicity, secondary endpoint is progression-free survival and response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>3 months</time_frame>
    <description>Determination the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of carbon ion radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Follow-up until progression up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Carbon Ion Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon Ion Radiotherapy</intervention_name>
    <description>Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E</description>
    <arm_group_label>Carbon Ion Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed HCC or diagnosis of HCC according to AASLD-guidelines&#xD;
&#xD;
          -  macroscopic tumor&#xD;
&#xD;
          -  liver-confined disease without extrahepatic disease as diagnosed by CT, MRT,&#xD;
             ultrasound and bone scan&#xD;
&#xD;
          -  minimal distance of tumor edge to the intestines of 1cm&#xD;
&#xD;
          -  age ≥ 18 years of age&#xD;
&#xD;
          -  Karnofsky Performance Score ³60&#xD;
&#xD;
          -  For women with childbearing potential, (and men) adequate contraception.&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of the clinical&#xD;
             trial&#xD;
&#xD;
          -  Written informed consent (must be available before enrolment in the trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal of the patients to take part in the study&#xD;
&#xD;
          -  previous radiotherapy of the hepatobiliary system&#xD;
&#xD;
          -  margin of &lt; 1cm between tumor edge and intestines&#xD;
&#xD;
          -  Patients who have not yet recovered from acute toxicities of prior therapies&#xD;
&#xD;
          -  Known carcinoma &lt; 2 years ago (excluding Carcinoma in situ of the cervix, basal cell&#xD;
             carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment&#xD;
             interfering with study therapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Participation in another clinical study or observation period of competing trials,&#xD;
             respectively&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Heidelberg, Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Prof. Dr. Dr. Jürgen Debus</investigator_title>
  </responsible_party>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

